Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

Core Viewpoint - Alnylam Pharmaceuticals has announced a new five-year strategy called "Alnylam 2030," aimed at scaling operations, achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility [1] Group 1: Strategic Focus - The strategy emphasizes achieving leadership in ATTR amyloidosis, a key area for the company [1] - The company aims to drive long-term growth through sustainable innovation, indicating a commitment to research and development [1] - Financial discipline and agility are highlighted as essential components for delivering exceptional results [1] Group 2: Financial Performance - Alnylam reported preliminary fourth quarter and full year 2025 global net product results, although specific figures were not disclosed in the announcement [1]